Duromine vs Qsymia



Duromine and Qsymia are drugs used in treatment of obesity and excessive weight. Duromine and Qsymia diet pills combined with active lifestyle and a low-calorie diet are prescribed for therapy of overweight or obesity, accompanied by comorbidities (e.g. high blood pressure, diabetes or high blood cholesterol).

Manufacturers of Duromine and Qsymia

Duromine is a weight loss drug, active substance of which is Phentermine. Phentermine drug has been used in anti-obesity treatment since 1959. Duromine trademark was approved in Australian register of therapeutic goods in July 1991.

Phentermine is available under the trademark in Australia, as well as New Zealand, South Africa and Malaysia. Duromine manufacturer is iNova Pharmaceuticals, a subsidiary of Valeant Pharmaceuticals International Inc.

Qsymia is a combined weight loss drug, approved by the FDA for a long-term obesity treatment in 2012. Qsymia consists of two FDA approved drugs - Phentermine and Topiramate.

Phentermine was approved by the FDA for a short-term weight loss in overweight or obese adults. Topiramate is meant for the treatment of some seizures in epileptic patients, as well as for prevention of migraines. Manufacturer of Qsymia diet pills is Vivus Inc.

Pharmaceutical form of weight loss pills

iNova produces Duromine in capsules with an ion-exchange resin complex. On the market, people can find:

  • Duromine 15 mg
  • Duromine 30 mg
  • Duromine 40 mg

Vivus Inc. produces Qsymia in extended-release capsules. Qsymia capsules are available in 4 different dosages:

  • Qsymia 3.75 mg / 23 mg (Phentermine 3.75 mg and Topiramate 23 mg)
  • Qsymia 7.5 mg / 46 mg (Phentermine 7.5 mg and Topiramate 46 mg)
  • Qsymia 11.25 mg / 69 mg (Phentermine 11.25 mg and Topiramate 69 mg)
  • Qsymia 15 mg / 92 mg (Phentermine 15 mg and Topiramate 92 mg)

Mechanism of action of Duromine and Qsymia

Phentermine is a component of Duromine and Qsymia. This sympathomimetic amine is similar by its pharmacological effect to prototype of amphetamine of this class. Phentermine affects the production of catecholamines in hypothalamus, which reduces the appetite and the amount of food people eat every day.

Topiramate is known as a drug effective against migraines and seizures, which has one side effect – weight loss. An exact effect of Topiramate on excess weight is unknown. Supposedly, an effect of Topiramate on weight management is associated with appetite suppression and increased satiety.

Combination of Phentermine and Topiramate pharmacological effects increases the activity of gamma-aminobutyric acid (GABA) neurotransmitter, which affects functions of the central nervous system.

Duromine and Qsymia dosage

Duromine weight loss drug is designated for a short-term treatment of obesity in people with BMI over 30 or BMI 25 and higher, but with diseases, caused by extra weight. It is recommended to begin anti-obesity therapy with Duromine 30 mg. Duromine diet capsules should be taken in the morning before breakfast or within an hour or two after meal.

If Duromine 30 mg caused side effects (allergic reaction, sleeplessness, nausea and diarrhea), then the daily dose of Duromine can be reduced down to a minimal dose of Duromine 15 mg.

If anorexigenic effect is weak or does not appear at all after the intake of Duromine 30 mg, a single dose of Duromine can be increased up to Duromine 40 mg. Duromine 40 mg is a maximal daily dose. When exceeding the dose of Duromine 40 mg, the risk of tolerance to overdosage increases.

Duration of anti-obesity therapy with Duromine is 12 weeks. Taking Duromine pills for a longer time does not provide weight loss. If needed, a patient can repeat the therapy with Duromine, but no sooner than three months after the last dose of Duromine was taken.

Qsymia combined weight loss drug is meant for a long-term treatment of obesity. It is recommended to start the drug therapy of obesity with Qsymia 7.5 mg / 46 mg extended-release capsules. If 12 weeks after the intake of Qsymia capsules, the body mass has reduced by less than 3% of the initial weight, it is recommended to increase a single dose of Qsymia up to 15mg / 92mg.

If 12 weeks after the application of a higher dose of Qsymia 15mg / 92mg a person loses less than 5% of the initial body mass, then he should stop Qsymia anti-obesity therapy. Further use of Qsymia in the same or higher dose will hardly help to get clinically significant weight loss.

During a pharmacotherapy with Qsymia, doctors recommend to estimate the lost kilograms every 12 weeks. According to the results, the doctor decides whether a patient should stop using Qsymia or continue the anti-obesity therapy using a higher dose of Qsymia.

Some obese people achieve a significant weight loss when taking a minimal dose Qsymia 3.75 mg / 23 mg. In most cases, patients need maximum doses - Qsymia 7.5 mg / 46 mg or Qsymia 15 mg / 92 mg. In rare cases, people get weight loss only when they take a maximum dose of Qsymia 15 mg / 92 mg.